Search
Dolastatin 10
go.drugbank.com/drugs/DB12730InvestigationalDolastatin 10 has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Liver Cancer, and Kidney Cancer, among others.
CGI-1842
go.drugbank.com/drugs/DB12744InvestigationalJI-101 has been used in trials studying the treatment of Cancer, Colon Cancer, Neuroendocrine, Ovarian Cancer, and Advanced Solid Tumors.
OMS1620
go.drugbank.com/drugs/DB33930ExperimentalOMS1620 is under investigation in clinical trial NCT07811089 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620).
Ecopipam
go.drugbank.com/drugs/DB12273InvestigationalEcopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior.
Zelquistinel
go.drugbank.com/drugs/DB19336InvestigationalZelquistinel is under investigation in clinical trial NCT06547489 (GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder).
Emibetuzumab
go.drugbank.com/drugs/DB11849InvestigationalEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
Bavisant
go.drugbank.com/drugs/DB12299InvestigationalBavisant has been used in trials studying the basic science and treatment of Alcoholism, Pharmacokinetics, Drug Interactions, Attention Deficit Hyperactivity Disorder, and Attention Deficit Disorders With
Fresolimumab
go.drugbank.com/drugs/DB12396InvestigationalFresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis
Lumretuzumab
go.drugbank.com/drugs/DB12683InvestigationalLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
ENTR-601-44
go.drugbank.com/drugs/DB17836InvestigationalENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]